Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

45-day funding bill OK'd
Fatally shoved an old woman
Ex-sheriff shoots salesman
Won’t cover father’s case
Judge blocks two provisions
'I don't know who we are'
Turkey suicide bombing
Australia's 'scorching' heat
Body found on 5 Freeway
3-day wait to buy guns
Fined $87K for rough play
S. Korea Sept exports fall
Post-race altercation
Spain nightclub fire kills 7
CN's lottery ticket sales soar
Slams House stopgap bill
Appeals against polarization
To miss Hornets camp
Green suffers ankle injury
Bautista to undergo surgery
Misses another match
Jackpot swells to $1B
Whale capsizes boat, 1 dead
1990 murder victim ID’d
Tests COVID positive
Parasite found in lake
Locked woman in a cell?
Fed agency sues Chipotle
Renaissance tour movie
Addresses Tupac's murder
‘One day at a time'
Becky G embraces heritage
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
162,000 results
2d
First FDA Approved Drug to Slow Alzheimer’s
Joan was diagnosed with early-stage Alzheimer’s disease. There was nothing doctors could do. But now, a recently FDA-approved ...
朝日新聞社12d
Alzheimer’s drug Leqembi has full FDA approval
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 JST Share Tweet list Print This image provided by Eisai in January 2023 shows vials and packaging for ...
10don MSN
Medical Moment: FDA approves first-ever drug to slow Alzheimer’s
There is no cure yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.
2d
FDA advisers vote against experimental ALS treatment pushed by patients
The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm’s stem cell-based treatment has not ...
朝日新聞社3d
US approves Alzheimer’s drug that modestly slows disease
FDA approves much-debated Alzheimer’s drug panned by experts June 8, 2021 Alzheimer’s drug from Eisai and Biogen slows cognitive decline, side-effects in focus ...
Washington Examiner1mon
FDA needs to let go of its risk-averse regulatory model
The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data.
5d
After US approval, Japan approves Leqembi, its first Alzheimer's drug
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
The Financial Times27d
Vivek Ramaswamy’s FDA ‘corruption’ claims disavowed by Roivant
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
1don MSN
FDA wants to regulate thousands of lab tests that have long skirted oversight
The Food and Drug Administration says it plans to begin regulating laboratory-based medical tests. It's a multibillion-dollar industry that regulators say poses a growing risk to patients.
WTOP News17d
New Treatments for Alzheimer’s Disease
For anyone who has or knows someone who has Alzheimer’s disease, a progressive and irreversible form of dementia that’s ultimately deadly, it can sometimes be difficult to find hope.
WISH-TV
3d
Health Spotlight: First FDA-approved drug to slow Alzheimer’s
More than 6,000,000 Americans are living with Alzheimer's disease – it slowly steals your memories and takes away your mind ...
5d
After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices